Why Summits’ Post

We are very much looking forward to getting the community back together this fall for #ExecutiveDecisionMaking 2024. Review the newly release preliminary agendas and take advantage of early savings and secure your spot to join seasoned bio pharma strategic and operational leaders to delve into new approaches and share best practices. #portfoliomanagement #resourcemanagement

Looking forward to speaking at CHI's 21st Annual Executive Decision Making for Pharma and Biotech conference. Join my session to: Unlock the Power of Change: Elevate Your Leadership Journey As a forward-thinking leader, you wield the power to orchestrate transformative change within your organization. Yet, amidst the dynamic landscape of progress, do you possess the essential toolkit to navigate inevitable challenges and conflicts, ensuring collaboration prevails over escalation? Join us for an engaging session where you'll uncover not only the five critical pillars of effective change management but also strategies for adept conflict resolution. Gain invaluable insights to steer your organization towards a future of innovation, resilience, and sustainable growth. Seize this transformative opportunity to elevate your leadership prowess and drive impactful change. #leadership #innovation #change #changemanagement #conflictresolution #decisionmaking Bridget Kotelly Micah Lieberman

Transforming from a Distributed to a Centralized Portfolio Management Function: Considerations and Lessons Learned with Stephen Cho Novartis As Novartis transformed to a focused, pure-play innovative medicines company, portfolio management was consolidated across Research, Development, and Commercial to build lasting impact and achieve long-term business success. Since mid-2022, we have focused on building a stronger, focused pipeline, streamlined enterprise governance, centralized long-term revenue forecasts and valuations, and created an aligned strategic framework. Key learnings include importance of change management, flexibility, and streamlined processes and systems. #PortfolioManagement #ExecutiveDecisionMaking https://bit.ly/3Qk5qFU

I stepped out of my comfort zone and attended the Executive Decision Making for Pharma & Biotech conference this week. Here were my key learnings from a group of Portfolio and Program Managers: Strategic thinking in drug development starts with the Target Product Profile (TPP). You can't really guide development if you don't know what you are building for. Program Management owns the TPP. They are the only ones besides the CEO that touch the entire organization and can be thought of as mini-CEOs. Based on an in-conference survey, the biggest challenge faced by PPMs is subjectivity caused by human bias. The aim is to develop as much of an objective, data-driven process as possible. GRIDALL is the new acronym (Goals, Risks, Issues, Decisions, Actions, and Lessons Learned) for project management. It documents goals and insights gained and places them into the right order. Two definite advantages over ADI and RAID logs. A day late in drug development program management can be a day lost for the patients. #patientsarewaiting I want to thank Saeid (Sam) Yazdani, Mike Myers, Joe Stalder, Edoardo Madussi, Paul B Cook, PhD, PMP, Gary Summers and many others for their insights and willingness to answer my rudimentary questions. A special shout out to Bridget Kotelly and Cambridge Healthtech Institute for putting on such a great event. #drugdevelopment #executivedecisionmaking #programmanagement https://lnkd.in/eW-DJJ4C

The Partnership between Decision Sciences and Project Management to Enable Decision Quality in Drug Development at Eli Lilly Charles Persinger Eli Lilly and Company Decisions in drug development have a substantial influence on the outcome of individual projects and the Research and Development portfolio. Lilly Decision Sciences and Project Management organizations partner to deliver Decision Quality on decisions across Research and Development and Lilly Research Labs has won the Raiffa-Howard Award from the Society of Decision Professionals for achieving Organizational Decision Quality. This presentation will discuss what roles the Decision Sciences experts and Project Managers take and what approaches are put in place in those organizations to deliver Decision Quality for individual projects and the portfolio.  https://bit.ly/3Qk5qFU #ExecutiveDecisionMaking #PortfolioManagement #ProgramManagement

Launching a pharma product in your country and feeling unsure which KPIs to select...? You’re not alone, we often hear participants at our "Effectively Leading Country Launches in Pharma" course say they find this challenging! Yet incorporating the right KPIs is essential for a successful brand launch. 😅 Luckily, we’ve got you covered with some great insights today from CELforPharma faculty member and launch expert Jo Lopez! 👉 Swipe left for best practices in selecting those indicators that will ensure strategic alignment and operational success - ensuring your country-level launch stays on course. 🚀 -------- ☝️ I am Inge 🔥 My mission: Helping Pharma managers acquire business-critical competencies to make better decisions Liked this post? Want to see more? 🔔 Ring the bell on my Profile to get notified 🔝 Connect with me #pharma #launchexcellence #launch #pharmamarketing Uptake

[WHITEPAPER - Launch Excellence – Moments of Truth 🔥] - Our latest white paper, Launch Excellence: Moments of Truth, dives into the essentials for supercharging product launches, emphasizing the role of agile communication with stakeholders. Discover insights from industry experts: Catarina Santos from Novartis, Cathrin Schaefer from BeiGene, Marc van Unen, from Bristol Myers Squibb and Duncan Trew from 60seconds.com, and learn why good communication is key to brand success and patient outcomes. Download here - https://lnkd.in/e79xsmR8 #coaching #leadership #pharma #whitepaper #pharmaphorum #success #medicalaffairs #commercial #digital #lifesciences

🚀 Are you ready for a shift in your approach to 2025 planning? Join Dr. Wendy Heckelman and Richard Baron on September 24, 2024, at 12:30 PM for our exclusive webinar, "The 70% Trap: Conquering Change Failure in Biopharma Commercial Organizations." In this insightful session, you'll learn about the common pitfalls organizations face during change implementation and how to navigate them effectively. We'll delve into strategies that have proven successful in overcoming resistance and ensuring that change initiatives lead to tangible results. Discover the importance of aligning your teams, fostering a culture of adaptability, and leveraging data-driven insights to support your change efforts. Don't miss this opportunity to gain valuable knowledge and tools that will enhance your strategic success in the biopharma industry. Secure your spot now! 👉 Register Here: https://lnkd.in/eTr2pMe7 #Biopharma #ChangeManagement #ChangeLeadership #2025Planning #WLH

HRV Global LifeSciences - how it all began & where we are heading to: Listen to our CEO & pharmapreneur Hari Kiran Chereddi who shares insights on lifting global pharma to the next level in an exclusive interview with U.S. top podcast Coruzant Technologies, in conversation with Coruzant CEO Brian Thomas, MBA, FACHT. 👇 🎙️ 👍

The European #healthcare sector logged 363 deals for a EUR 16.8bn total deal volume in 1H24, compared to 479 deals worth EUR 30.5bn in 1H23. 👉 Megadeals missing in action, but potentials in pipeline 👉 Healthcare M&A deal volumes down 45% in first half 👉 PE buyers to help drive activity as interest rates ease So far there were only sub-3bn euro transactions, like  👉 Mercks acquisition of EyeBio 👉 Novartis’ EUR 2.7bn takeover of MorphoSys. Potentials in the pipeline are: 👉 Sanofi’s EUR 20bn spinoff/sale of its consumer health unit 👉 The potential EUR 11bn sale/IPO of STADA Group Want to know more about the upcoming M&A Deals? Follow me and Datasite with our Forecaster report. #Wheredealsaremade #Investmentbanking #mergersandacquisitions #SwissMA